Logo.PNG
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 18h28 HE | HilleVax, Inc.
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
03 janv. 2024 07h00 HE | Athira Pharma, Inc.
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Hyloris Announces Po
Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029)
26 déc. 2023 12h00 HE | Hyloris Pharmaceuticals SA
Valacyclovir is an Antiviral Medication that is Commonly Used to Treat Infections Caused by Herpes Viruses Clinical Study Demonstrates Comparable Relative Bioavailability to Valaciclovir Tablets under...
Hyloris Annonce des
Hyloris Annonce des Résultats Cliniques Positifs pour son Produit Valacyclovir (HY-029) en suspension orale
26 déc. 2023 12h00 HE | Hyloris Pharmaceuticals SA
Valacyclovir est un Médicament Antiviral Couramment Utilisé pour Traiter les Infections Causées par les Virus de l'HerpèsL’Etude Clinique a Démontré une Biodisponibilité Comparable à celle des...
Apnimed.png
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
21 déc. 2023 08h30 HE | Apnimed, Inc.
-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- Part of a two-study...
23andMe_Logo_grey.png
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
19 déc. 2023 08h00 HE | 23andMe, Inc.
Thirty additional patients with advanced neuroendocrine and advanced ovarian cancer will be enrolled in the study of 23ME-00610, an investigational antibody targeting CD200R1 A second potentially...
Fundable for Life, Inc. Partners with Boston BioLife to Provide its Members TV and Digital Print Media Along with Funding Options
18 déc. 2023 08h00 HE | Fundable for Life, Inc.
Fundable for Life, Inc. provides business owners channels for media exposure and funding options so they can grow their businesses.
logo.jpg
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
15 déc. 2023 07h22 HE | AC Immune SA
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of...
logo color s and clearside.jpg
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
14 déc. 2023 07h05 HE | Clearside Biomedical, Inc.
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors
14 déc. 2023 04h00 HE | AKAMPION
YONGIN, South Korea, December 14, 2023 – 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative...